Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 105Gastrointestinal 4Other solid neoplasm 2Genitourinary 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6870Lung Neoplasms 5102Small Cell Lung Carcinoma 1166Breast Neoplasms 855Neoplasms 762Colorectal Neoplasms 668Melanoma 566Ovarian Neoplasms 506Neoplasm Metastasis 480Pancreatic Neoplasms 472Adenocarcinoma of Lung 397Stomach Neoplasms 396Prostatic Neoplasms 370Head and Neck Neoplasms 367Carcinoma, Renal Cell 350Esophageal Neoplasms 337Squamous Cell Carcinoma of Head and Neck 325Mesothelioma, Malignant 324Colonic Neoplasms 293Mesothelioma 289Urinary Bladder Neoplasms 262Brain Neoplasms 254Uterine Cervical Neoplasms 243Triple Negative Breast Neoplasms 222Sarcoma 197Endometrial Neoplasms 196Carcinoma, Hepatocellular 186NSCLC 167Pleural Effusion, Malignant 160Kidney Neoplasms 160

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Breast Cancer × Thoracic × Clear all
NCT05514717 2025-07-11

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

Mersana Therapeutics

Phase 1 Recruiting
162 enrolled
BreastGastrointestinalThoracic

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡